Chimerix’s (CMRX) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Chimerix (NASDAQ:CMRX) in a research note released on Wednesday morning,Benzinga reports. The brokerage currently has a $11.00 price objective on the biopharmaceutical company’s stock. HC Wainwright also issued estimates for Chimerix’s Q4 2024 earnings at ($0.24) EPS, Q1 2025 earnings at ($0.29) EPS, Q2 2025 earnings at ($0.32) EPS, Q3 2025 earnings at ($0.33) EPS, Q4 2025 earnings at ($0.31) EPS, FY2025 earnings at ($1.26) EPS and FY2026 earnings at ($0.99) EPS.

A number of other research firms have also recently weighed in on CMRX. Wedbush reiterated an “outperform” rating and set a $6.00 price target on shares of Chimerix in a report on Tuesday. StockNews.com raised shares of Chimerix from a “sell” rating to a “hold” rating in a research note on Wednesday, August 21st.

Chimerix Stock Performance

Shares of Chimerix stock opened at $2.95 on Wednesday. The firm has a market capitalization of $265.32 million, a price-to-earnings ratio of -3.14 and a beta of 1.02. Chimerix has a fifty-two week low of $0.75 and a fifty-two week high of $3.39. The stock has a 50 day moving average of $1.07 and a 200 day moving average of $0.96.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the company. Marshall Wace LLP purchased a new position in Chimerix during the 2nd quarter valued at about $137,000. Connor Clark & Lunn Investment Management Ltd. boosted its stake in shares of Chimerix by 66.8% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 344,712 shares of the biopharmaceutical company’s stock valued at $321,000 after purchasing an additional 138,098 shares during the period. Finally, Valeo Financial Advisors LLC boosted its stake in shares of Chimerix by 566.9% in the third quarter. Valeo Financial Advisors LLC now owns 81,766 shares of the biopharmaceutical company’s stock valued at $76,000 after purchasing an additional 69,505 shares during the period. 45.42% of the stock is currently owned by hedge funds and other institutional investors.

About Chimerix

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.